The Subscription Model (led by the UK) provides tariffs for guaranteed annual fees payable to the innovator of any new approved antimicrobial treatment which is made available to the National Health Service (NHS).

The commercial landscape for antibiotics is changing dramatically. International governmental and multinational corporate interest are creating a more remunerative environment, promising much-improved ROI.

MetalloBio is a value growth investment focused on commercialising its antibiotic drug candidates post-Phase 2 trials, primarily through licensing, while remaining open to other opportunities like mergers and acquisitions.